Welcome to our dedicated page for BioStem Technologies news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on BioStem Technologies stock.
BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (OTC: BSEM) is sponsoring the MRO Better Half Dash, a popular annual NASCAR event, on May 29, 2024, at Trackhouse Motorplex in Mooresville, NC. This event features wives and girlfriends of professional racing drivers in competitive go-kart races, showcasing their talents and providing a unique spectacle for fans. Key participants include Ariana Jencik and Parker Retzlaff. Ariana, who has a background in racing and graduated from the NASCAR Technical Institute, will be competing part-time in the Late Model division. Parker Retzlaff, a prominent driver in the NASCAR Xfinity Series, praised the event for giving women a platform to shine. The event supports Darby's Warrior Support, a cause dedicated to assisting soldiers. CEO of BioStem Technologies, Jason Matuszewski, emphasized the company's pride in supporting this meaningful cause. The event will be aired on Fox Sports 1 on June 5th.
BioStem Technologies reported a record first quarter revenue of $41.9 million for 2024, marking a significant 71-fold increase from $0.6 million in Q1 2023. This impressive growth is attributed to the commercial success of AmnioWrap2®, a placental-derived allograft product. Gross profit surged to $39.7 million, representing 95% of revenue, up from 82% in the same period last year. The company also achieved a positive GAAP net income for the first time, reflecting strong financial health. Operationally, BioStem completed a two-year audit, expanded processing capacity, and enhanced its clinical capabilities. Key developments include the USPTO's prioritized examination of a critical patent and the engagement of McCoy Clinical Consulting for clinical trials.
BioStem Technologies Inc. (OTC: BSEM) will report its first quarter 2024 financial results on Tuesday, May 14, 2024. The leading biotechnology company specializes in placental derived allografts for advanced wound care. A conference call and webcast discussing the financial results and corporate updates will be held at 4:30 pm ET on the same day.
BioStem Technologies Inc. (OTC: BSEM) has been granted Prioritized Examination by the USPTO for its patent application on STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. This patent protects BioStem's method of processing human amniotic tissue, important for wound care treatment. The global wound care dressing market is projected to grow at a CAGR of 4.16% from 2024 to 2030.
BioStem Technologies Inc. (OTC: BSEM) has hired Nick McCoy to lead the Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials for their BioREtain Allografts. These trials aim to meet the evolving reimbursement landscape requirements and ensure patient access to their products. McCoy's extensive experience in clinical research will help accelerate the completion of trials and demonstrate the real-world benefits of BioStem's products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.